KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non-Current Assets (2016 - 2025)

Acadia Pharmaceuticals has reported Other Non-Current Assets over the past 16 years, most recently at $7.8 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $7.8 million for Q4 2025, up 2085.24% from a year ago — trailing twelve months through Dec 2025 was $7.8 million (up 2085.24% YoY), and the annual figure for FY2025 was $7.8 million, up 2085.24%.
  • Other Non-Current Assets for Q4 2025 was $7.8 million at Acadia Pharmaceuticals, up from $3.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for ACAD hit a ceiling of $9.5 million in Q2 2025 and a floor of $359000.0 in Q4 2024.
  • Median Other Non-Current Assets over the past 5 years was $5.8 million (2021), compared with a mean of $5.9 million.
  • Biggest five-year swings in Other Non-Current Assets: crashed 93.78% in 2024 and later skyrocketed 2085.24% in 2025.
  • Acadia Pharmaceuticals' Other Non-Current Assets stood at $5.8 million in 2021, then changed by 0.0% to $5.8 million in 2022, then changed by 0.0% to $5.8 million in 2023, then crashed by 93.78% to $359000.0 in 2024, then skyrocketed by 2085.24% to $7.8 million in 2025.
  • The last three reported values for Other Non-Current Assets were $7.8 million (Q4 2025), $3.0 million (Q3 2025), and $9.5 million (Q2 2025) per Business Quant data.